Fungi and non-tuberculous mycobacteria: emerging pathogens in cystic fibrosis


Article ID: 4981
Vol 36, Issue 1S1, 2022
DOI: https://doi.org/10.23812/j.biol.regul.homeost.agents.202236.1S1.23
Received: 11 March 2022; Accepted: 11 March 2022; Available online: 11 March 2022; Issue release: 11 March 2022

Abstract

Fungi and non-tuberculous mycobacteria (NTM) are increasingly isolated in the sputum of patients with cystic fibrosis (CF), often representing a diagnostic-therapeutic problem for the clinician. For this, it is essential to start screening programs for these pathogens in all patients with CF, especially in individuals with an otherwise unexplained deterioration of lung function. Infections sustained by these pathogens are also a significant cause of morbidity and mortality in the post-transplant period. Early diagnosis and treatment play a central role in the management of all CF patients


Keywords

cystic fibrosis;fungi;mycobacteria;NTM;treatment;Aspergillus


References

Supporting Agencies



Copyright (c) 2022




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).